TLP
TEVA icon

Tri Locum Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Tri Locum Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-445,900
Closed -$4.41M – 42
2021
Q2 		$4.41M Buy
+445,900
New +$4.72M 1.44% 20

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tri Locum Partners's TEVA Position: Q1 2026 in Review

Tri Locum Partners reduced its Teva Pharmaceuticals (TEVA) stake by 29% in Q1 2026, selling an estimated $13.3M and leaving 1,021,008 shares worth $30.8M. The position accounts for 4.32% of the portfolio, ranked #11.

Tri Locum Partners first reported a position in TEVA in Q3 2022 and has held it in 13 quarters since. The position peaked at $53.4M in Q4 2024. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Tri Locum Partners held 1,021,008 shares of Teva Pharmaceuticals worth $30.8M as of Q1 2026.
  • Tri Locum Partners sold 414,857 Teva Pharmaceuticals shares in Q1 2026, an estimated $13.3M.
  • Teva Pharmaceuticals made up 4.32% of Tri Locum Partners's portfolio in Q1 2026, its #11 holding.
  • Tri Locum Partners first reported a position in Teva Pharmaceuticals in Q3 2022 and has held it in 13 quarters since.
  • Tri Locum Partners's Teva Pharmaceuticals position peaked at $53.4M in Q4 2024.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Tri Locum Partners's 13F filing for Q1 2026, filed 18 May 2026.